SAGE Therapeutics (SAGE) : acquisition proposal from Biogen (BIIB)

• SAGE Therapeutics (SAGE) was acquired by Supernus Pharma (SUPN). (31 Jul 2025)

 

 

 

 

  

 

 

SAGE Therapeutics confirms receipt of acquisition proposal from Biogen (BIIB) 

• Sage Therapeutics, Inc. (SAGE) confirmed that Biogen Inc. (BIIB) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
• Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.

SAGE Therapeutics (SAGE) reports Phase 2 Brexanolone clinical data

  

monthly

SAGE Therapeutics reports Phase 2 Brexanolone (SAGE-547) clinical data published in The Lancet:

Co announced that The Lancet has published results from a Phase 2, double-blind, randomized and placebo-controlled study of brexanolone (SAGE-547) in women with severe postpartum depression.

• The study found that treatment with brexanolone resulted in a clinically meaningful and statistically significant mean reduction in the 17-item Hamilton Rating Scale for Depression total score, a common measure of depression severity, that began at 24 hours and was maintained at similar magnitude until the 30-day follow-up.
• Brexanolone was well-tolerated in this study with no observations of deaths, serious adverse events or discontinuations.
• Overall, fewer patients who received brexanolone experienced adverse events compared with placebo (4 of 10 on brexanolone and 8 of 11 on placebo).

SAGE Therapeutics (SAGE) : 6-month performance

SAGE Therapeutics (SAGE) began trading on the NASDAQ on 18 July 2014

Description

SAGE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (CNS) disorders. The Company’s initial product candidates include SAGE-547, SAGE-689 and SAGE-217. The lead product candidate in its SE program, SAGE-547, is an intravenous (IV), agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with therapeutic approaches, for the treatment of super-refractory SE (SRSE). The Company’s follow-on product candidates, SAGE-689 and SAGE-217, utilize similar mechanistic pathways as SAGE-547 and are designed to have pharmaceutical properties which optimize both their non-clinical profiles and potential clinical profiles for the treatment of different stages of SE. SAGE-NCE is being developed as an intravenous therapy, as well as an oral stepdown therapy for status epilepticus and other seizure disorders.

Address

215 1st St
CAMBRIDGE, MA 02142-1213
United States

Website 

www.sagerx.com

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-71.12%	-317.19%
Return on average equity	-	-
Employees	25